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Abstract
Recent studies have shown that adipose tissue is an
active endocrine and paracrine organ secreting
several mediators called adipokines. Adipokines
include hormones, inflammatory cytokines and other
proteins. In obesity, adipose tissue becomes
dysfunctional, resulting in an overproduction of
proinflammatory adipokines and a lower production
of anti-inflammatory adipokines. The pathological
accumulation of dysfunctional adipose tissue that
characterizes obesity is a major risk factor for many
other diseases, including type 2 diabetes,
cardiovascular disease and hypertension. Multiple
physiological roles have been assigned to adipokines,
including the regulation of vascular tone. For
example, the unidentified adipocyte-derived relaxing
factor (ADRF) released from adipose tissue has been
shown to relax arteries. Besides ADRF, other
adipokines such as adiponectin, omentin and visfatin
are vasorelaxants. On the other hand, angiotensin II
and resistin are vasoconstrictors released by
adipocytes. Reactive oxygen species, leptin, tumour
necrosis factor a, interleukin-6 and apelin share both
vasorelaxing and constricting properties. Dysregulated
synthesis of the vasoactive and proinflammatory
adipokines may underlie the compromised vascular
reactivity in obesity and obesity-related disorders.
Introduction
For a long time, adipose tissue or body fat was
believed to be simply involved in total body lipid and
overall energy homeostasis. White adipose tissue stores
excess energy in the form of triglycerides, while brown
adipose tissue is actively involved in the regulation of
body temperature [1,2]. However, in recent years, it
has become clear that adipose tissue is far more than a
storage facility and thermoregulator and is in fact an
active secretory organ of multiple mediators known as
adipokines [3]. These adipokines include hormones
(for example, leptin and adiponectin), inflammatory
cytokines (for example, tumor necrosis factor a
(TNFa), interleukin (IL)-6, omentin and visfatin) and
other proteins (for example, plasminogen activator
inhibitor (PAI)-1, angiotensinogen, resistin and apelin)
[4,5]. Furthermore, adipose tissue is known to release
an as yet unidentified adipocyte-derived relaxing factor
(ADRF) [6] which relaxes several arteries. Here we give
an overview of the influence of different adipokines on
vascular tone and on their potential role in obesity and
obesity-related disorders.
Adipokines
Adipose tissue (see “Adipose tissue” text box below) is
known to produce and release numerous bioactive sub-
stances, known as adipokines, into its direct surround-
ings (auto- or paracrine) and into the bloodstream
(endocrine) [3]. Adipokines are involved in various phy-
siological processes (Table 1), including the regulation
of arterial tone [4,7]. Therefore, adipose tissue affects
not only overall metabolism but also the functionality of
many organs and tissues, such as muscle, liver, brain
and the vasculature. Total absence of adipose tissue has
been reported to be associated with nonviability, which
emphasizes the essential role of adipose tissue in human
physiology [8]. Maintenance of a normal amount of adi-
pose tissue is essential because imbalance can cause ser-
ious health problems and dysregulated release of
adipokines may lead to vascular disturbances and
inflammation.
Vasoactive adipokines in physiology and obesity
Under normal circumstances, vascular tone is influenced
by adipokines (Figure 1 and Table 2). However, it is
thought that vascular tone regulation is compromised in
obesity and obesity-related disorders, in which the
amount of adipose tissue has grown out of proportion.
This eventually leads to a dysregulated synthesis of
vasoactive adipokines by dysfunctional adipose tissue in
favour of harmful proinflammatory adipokines (for
example, leptin) [7] (Figure 2). The dysregulated synth-
esis and/or secretion of adipokines and the infiltration
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of macrophages into adipose tissue, possibly as a result
of monocyte chemoattractant protein (MCP)-1 [9] and
leptin [10] release from adipocytes, lead to a state of
inflammation within adipose tissue. A proinflammatory
state in adipose tissue can induce not only a dysregula-
tion of vascular tone but also local insulin resistance,
adhesion of monocytes, vascular remodelling, foam cell
formation in the arterial wall and endothelial dysfunc-
tion. Endothelial dysfunction is reflected as a decrease in
nitric oxide (NO) bioavailability, endothelium-dependent
relaxation and impaired ability of the endothelium to
respond to circulating hormones. All of these changes
clearly promote the development of cardiovascular dis-
eases and type 2 diabetes [11].
It has been proposed that hypoxia underlies this
inflammatory response, as hypoxia occurs in areas of fat
depots when the vascular oxygen supply is compromised
because of tissue mass expansion [4]. Direct evidence
that growing adipose tissue becomes hypoxic has recently
been shown in mice [12,13]. Furthermore, cell culture
studies using murine and human adipocytes strongly sup-
port the modulatory role of hypoxia in the production of
several proinflammatory adipokines [14,15].
Furthermore, angiogenesis is promoted in response to
hypoxia [16]. Novel vascularisation can be considered an
automatic fail-safe to counter hypoxia and ensure suffi-
cient nutrient and oxygen supply to the different tissues.
Hypoxia upregulates inducible transcription factors,
which trigger the expression of angiogenic adipokines
such as vascular endothelial growth factor (VEGF),
hepatocyte growth factor and PAI-1 [7], which promote
vascular endothelial cell proliferation and the later
stages of new vessel formation [17]. Also, other adipo-
kines, such as leptin, basic fibroblast growth factor and
IL-6, have been shown to induce angiogenesis, while
adiponectin and TNFa have pro- and antiangiogenic
properties [17]. The vasoactive adipokines and their role
in physiological conditions as well as in obesity and
obesity-related disorders are described in more detail in
the following subsection.
Adipokines with vasorelaxing and vasocontractile
properties
Reactive oxygen species
Reactive oxygen species (ROS) are a class of oxygen-
derived molecules including superoxide anion and
hydrogen peroxide, both of which are modulators of
vascular tone. Vascular smooth muscle cells, endothe-
lium and perivascular adipose tissue are known to
contain ROS [18].
Superoxide anions can induce vasoconstriction
through Ca2+ sensitization pathways, although it is not
Adipose tissue
Adipose tissue is predominantly located around blood vessels
(perivascular), around internal organs (visceral or abdominal) or
subcutaneously. Adipose tissue consists of a heterogeneous mixture of
cellular structures (that is, adipocytes, precursor cells, macrophages,
fibroblasts and endothelial cells) and tissue structures (that is, small blood
vessels and nerve tissue) [147]. The predominant cell type in adipose
tissue is the adipocyte, which may be white or brown. In accordance
with the type of adipocytes which compose it, adipose tissue is
subdivided into white and brown adipose tissue.
White adipose tissue comprises up to 20% to 25% of total body
weight. In general, white adipose tissue acts mainly as an energy store or
reserve (that is, lipid storage) and expands during obesity. It also provides
thermal insulation (subcutaneous adipose tissue) and supports the body
against mechanical shocks (for example, skin or kidney) [1].
Brown adipose tissue regulates body temperature by lipid metabolism
in newborn mammals and some hibernating animals [2]. Recent studies
have shown that healthy adult humans still possess a substantial fraction
of metabolically active brown adipose tissue in the supraclavicular and
neck regions, along with some additional paravertebral, mediastinal,
paraaortic and suprarenal locations [148,149]. Although the obesity-
preventive role of brown adipose tissue has long been a matter of
debate, more recent data clearly show an inverse correlation between
body mass index and brown adipose tissue activity in humans [148,150].
Table 1 Physiological processes in which adipokines are
involveda
Physiological processes Adipokines involved
Glucose metabolism Adiponectin, resistin
Lipid metabolism CETP, retinol-binding protein
Immunity Adipsin
Inflammation TNFa, IL-6
Coagulation PAI-1
Maintaining normal reproduction Leptin, ghrelin
Pancreatic b-cell function IL-6, adiponectin, visfatin
Angiogenesis Leptin, VEGF, HGF
Feeding behaviour Leptin
Regulation vascular tone ADRF, leptin, adiponectin
aCETP, cholesteryl ester transfer protein; TNFa, tumor necrosis factor a; IL-6,
interleukin 6; PAI-1, plasminogen activator inhibitor 1; VEGF, vascular
endothelial growth factor; HGF, hepatocyte growth factor; ADRF, adipocyte-
derived relaxing factor.
Figure 1 Adipose tissue releases several adipokines. Some of
them have vasorelaxing or vasocontractile properties, while others
share both. ADRF, adipocyte-derived relaxing factor; ROS, reactive
oxygen species; TNFa, tumour necrosis factor a.
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clear whether they act directly or via conversion to
hydrogen peroxide [19]. Furthermore, contraction in
response to perivascular nerve activation by electrical
field stimulation is enhanced by superoxide anions from
perivascular adipose tissue [18].
Hydrogen peroxide is a more likely paracrine ROS
because hydrogen peroxide is not a free radical and
therefore more stable and less reactive with other tissue
radicals [20]. Hydrogen peroxide is known to induce
both vasorelaxation and vasoconstriction, depending on
species, type of vascular bed, concentration, membrane
potential and degree of obesity [20-22]. Vasorelaxation
is possibly induced by endothelium-dependent mechan-
isms involving the release of vasodilating cyclooxygenase
metabolites [23] and NO [24], as well as endothelium-
independent mechanisms [21] mediated by the activa-
tion of different potassium channels on smooth muscle
cells [23,25,26]. On the other hand, vasoconstriction by
hydrogen peroxide is likely induced in a Ca2+-dependent
way, although Ca2+ sensitization and Ca2+-independent
pathways have also been reported [20,24,27]. Further-
more, hydroxyl radicals, cyclooxygenase metabolites,
protein kinase C, phospholipase A2 phospholipase C and
tyrosine kinase appear to play a role in hydrogen perox-
ide-induced contractions [27].
Oxidative stress occurs when the production of ROS
exceeds the cell’s capacity to detoxify these potentially
injurious oxidants using antioxidant defense systems
[28]. In general, superoxide and hydrogen peroxide pro-
duction in adipose tissue is increased in obese mice,
which promotes endothelial dysfunction. Superoxide
anions impair endothelium-dependent vasorelaxation by
decreasing NO bioavailability via the formation of
peroxynitrite, which is in turn another ROS [29].
Furthermore, ROS contributes to endothelial dysfunc-
tion by upregulating the expression of adhesion and
chemotactic molecules in endothelial cells, which pro-
mote monocyte adhesion and migration to the vessel
wall [28]. The adhesion of these circulating blood cells
to vascular endothelium is a key element in the develop-
ment of inflammation and thrombosis within the vascu-
lature in vascular diseases associated with oxidative
stress, such as atherosclerosis [28].
Table 2 Vasoactive effect of adipokinesa
Adipokines Vasoactive effect References
Superoxide
anion
Vasoconstriction through Ca2+
sensitization; impairs EC-dependent
relaxation by decreasing NO
bioavailability; enhances
vasoconstriction to perivascular nerve
activation by electrical field stimulation
[18,19,29]
Hydrogen
peroxide
EC-dependent and EC-independent
vasorelaxation mediated by opening KCa,
Kv and KATP channels; Ca
2+-dependent
and Ca2+-independent vasoconstriction
[20,21,23-27]
Leptin Vasoconstriction due to sympathetic
nervous system activation; EC-
dependent and EC-independent
vasorelaxation
[31-34,38,39]
TNFa EC-dependent and EC-independent
vasorelaxation; triggers ET-1- and
Ang-induced vasoconstriction; impairs
EC-dependent vasorelaxation due to
decreased NO or increased ROS
production; reduces vasorelaxing effect
of PVAT due to increased ROS
production
[50,52,53,57-59]
IL-6 EC-independent vasorelaxation; reduces
vasorelaxing effect of PVAT due to
increased ROS production; impairs
endothelial function due to increased
ROS and decreased NO production
[59,66,67,72]
Apelin NO-dependent vasorelaxation; EC-
independent vasoconstriction
[76-78,80]
Adiponectin NO-dependent vasorelaxation
mediated by opening Kv channels
[59,90,91]
Omentin EC-dependent and EC-independent
vasorelaxation
[100]
Visfatin NO-dependent vasorelaxation [107]
ADRF Vasorelaxation through opening of
KATP, KCNQ or KCa channels depending
on the species
[6,92,112,114,115]
Ang II Vasoconstriction via binding on AT1
receptors
[124]
Resistin No effect on contractility of blood
vessels; impairs endothelial function
due to increased ET-1 production and
decreased NO production
[135,144]
aEC, endothelial cell; NO, nitric oxide; KCa channels, Ca
2+-activated K+
channels; Kv channels, voltage-dependent K
+ channels; KATP channels, ATP-
sensitive K+ channels; TNFa, tumor necrosis factor a; ET-1, endothelin 1; Ang,
angiotensinogen; ROS, reactive oxygen species; PVAT, perivascular adipose
tissue; IL-6, interleukin 6; Ang II, angiotensin II; AT1, angiotensin type 1; ADRF,
adipocyte-derived relaxing factor.
Figure 2 Relationship between dysfunctional adipose tissue in
obesity, inflammation, hypoxia, and obesity-related disorders.
Adipose tissue mass increases during obesity, which leads to a state
in which the adipose tissue becomes hypoxic. There is a
dysregulation in the synthesis of adipokines in favor of the
proinflammatory ones. This might lead to obesity-related disorders
and results in inflammation within adipose tissue. Hypoxia may
underlie this inflammatory response by supporting the production
of proinflammatory adipokines.
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Leptin
Leptin is almost exclusively secreted by white and
brown adipocytes [30]. Under normal conditions, leptin
contributes to blood pressure homeostasis by its vasore-
laxing and vasocontractile effects [31,32]. While the con-
tractile effect of leptin is attributed to sympathetic
nervous system activation [31], various mechanisms
seem to be responsible for leptin-induced vasorelaxation.
This latter effect can be endothelium-dependent, either
through the release of NO [33] or by other mechanisms
[32,34]. The involvement of the endothelium-derived
hyperpolarizing factor (EDHF) in leptin-induced vasore-
laxation remains controversial [32,35]. It has been pos-
tulated that epoxyeicosatrienoic acids (EETs) and/or
EDHF-dependent vasorelaxation in vivo might act as a
backup in case of reduced NO availability [36]. On the
other hand, EETs are able to activate endothelial NO
synthase and subsequently release NO to influence
arterial tone [37]. There is also evidence that leptin
affects vascular tone without endothelial involvement
[38]. A study on endothelium-denuded rat aortic rings
showed that leptin attenuated angiotensin II (Ang II)-
induced contraction by inhibiting Ca2+ release from the
intracellular stores in vascular smooth muscle cells [39].
Leptin levels are markedly increased in obesity [22,40].
Hyperleptinemia in obesity is believed to dysregulate
blood pressure, resulting in hypertension. Significant
associations have been found between plasma leptin
levels and hypertension in both males and females,
which makes leptin a potential predictor of hypertension
[41,42]. In obesity, endothelium-dependent vasorelaxa-
tion is likely to become less effective, as sustained
hyperleptinemia leads to endothelial dysfunction [43].
This might be the result of a leptin-induced increase of
vasoconstrictor endothelin-1 [44], a leptin-induced
expression of endothelin type A receptors in vascular
smooth muscle cells [45], a leptin-induced depletion of
NO and an increase of cytotoxic ROS [46]. Leptin also
promotes smooth muscle cell proliferation, contributing
to the increased peripheral vascular resistance [47].
Furthermore, it stimulates the release of proinflamma-
tory cytokines from macrophages, which may further
elevate blood pressure and exacerbate the inflammatory
process [48].
Tumor necrosis factor a
The cytokine TNFa is a potent, time-dependent vasocon-
strictor [49,50] and vasodilator [51-54]. Besides time
dependency, it is unclear what underlies the differential
regulation of arterial contractility by TNFa. Vasoregula-
tory actions of TNFa may be vascular bed-specific. Also,
differences in experimental protocols used may explain
the diversity of observations reported in various studies.
A source of TNFa that has recently been identified is
perivascular adipose tissue [55]. This implies that TNFa
is produced in the direct vicinity of the vascular
endothelium. TNFa-mediated vasoregulation can occur
through both endothelium-dependent [52] and endothe-
lium-independent mechanisms [53]. Some studies have
suggested that TNFa promotes vasorelaxation by an
increase of NO and prostaglandin production [52,54],
while another study has suggested the involvement of
hydrogen peroxide [56].
On the other hand, TNFa is able to induce vasoconstric-
tion by increasing endothelin-1 [57] and angiotensinogen
levels [58]. In addition, TNFa impairs endothelium-
dependent vasorelaxation in various vascular beds as a
result of a decrease in endothelial NO release or an
increase in NO scavengers such as ROS [50]. Moreover, a
recent study has shown a reduced vasorelaxing effect of
perivascular adipose tissue in response to TNFa and IL-6,
which upregulate ROS [59].
Increased adipose tissue expression of TNFa mRNA
has been reported in different rodent models of obesity
as well as in clinical studies involving obese patients
[40]. TNFa is considered a molecule that links inflam-
mation to obesity [40]. Moreover, the infiltration of
macrophages in adipose tissue during obesity contri-
butes to increased TNFa production [60]. The increase
in TNFa expression induces the production of ROS,
resulting in endothelial dysfunction in obesity and obe-
sity-related disorders such as hypertension, atherosclero-
sis and type 2 diabetes [61]. Furthermore, TNFa
decreases adiponectin expression [62] and stimulates the
secretion of proinflammatory proteins (for example,
IL-6), which contribute to the maintenance of the chronic
inflammatory state of adipose tissue in obesity [63].
Interleukin 6
A sustained increase in proinflammatory cytokine IL-6
plasma levels is associated with high blood pressure
[64,65]. On the other hand, acute exposure of IL-6
in vitro relaxes the aorta [66]. This vasorelaxing effect is
likely regulated by an endothelium-independent pathway
involving an increase in prostacyclin in vascular smooth
muscle cells. IL-6 also relaxes skeletal muscle resistance
vessels. However, this occurs only in vivo, suggesting
that IL-6 interacts with parenchymal or intravascular
factors to elicit vasorelaxation [67].
In obesity, an increase in cytokine IL-6 has been
observed at the mRNA and protein levels in white adi-
pose tissue [68,69]. IL-6 has been shown to be a predic-
tor of future myocardial infarction [65] and is highly
associated with cardiovascular mortality [70]. IL-6
induces the induction of hepatic C-reactive protein
(CRP) production, which is now known to be an inde-
pendent major risk factor for cardiovascular complica-
tions [40]. Some studies have suggested that IL-6 is
rather an indirect marker of vascular dysfunction, while
others have suggested a more active role in vascular
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dysfunction [71]. Long-term elevation of IL-6 in mice
has been shown to impair endothelial function by
increasing angiotensin II-stimulated production of ROS
as well as by reducing endothelial NO synthase mRNA
expression [72]. In addition, IL-6 enhances vascular
smooth muscle cell proliferation [73], which is a key
event in the genesis of atherosclerotic lesions.
Genetic deletion of IL-6 attenuates angiotensin
II-induced hypertension in mice [64], suggesting that
elevated IL-6 in obesity might contribute to hyperten-
sion via Ang II. In addition, IL-6 inhibits adiponectin
gene expression in cultured adipocytes [68], which may
exacerbate obesity-related hypertension.
Apelin
Apelin, of which different isoforms exist, acts through
the binding to a specific G protein-coupled receptor
named APJ [74], which is present on endothelial cells,
vascular smooth muscle cells and cardiomyocytes [75].
Apelin causes NO-dependent vasorelaxation of human
arteries both in vitro and in vivo [76,77]. In vivo exogen-
ous apelin administration has been shown to cause a
rapid NO-dependent fall in blood pressure in a rodent
model, confirming its powerful vasorelaxing effect [78].
However, some reports have associated apelin with an
increase in arterial pressure [79]. It has been proposed
that apelin-induced changes in blood pressure (that is,
an increase or decrease) are both dose- and time-depen-
dent [74]. Furthermore, it is also possible that the
observed bioactivity of apelin varies depending on spe-
cies and/or vascular bed. Other data also suggest that
apelin has vasoconstrictive potential by acting directly
on vascular smooth muscle cells. In endothelium-
denuded isolated human veins, apelin has been shown
to be a potent vasoconstrictor with nanomolar potency
and a maximum response comparable to that of Ang II
[80]. In the presence of functional endothelium, this
vasoconstrictive effect may be counterbalanced or even
masked by activation of APJ receptors on vascular
endothelial cells, resulting in the release of endothelial
vasodilator substances such as NO [81]. All of these
data taken together suggest a role for the apelin-APJ
system as a regulator of vascular tone.
Apelin production in adipose tissue is strongly upregu-
lated by insulin, and plasma concentrations are increased
in obese and hyperinsulinemic mice and humans [82]. In
contrast to acute exposure, long-term exposure of apelin
does not affect blood pressure [83], which might be
explained by resistance to its hypotensive effect. This is
in contrast to a study in which high apelin levels were
found to increase blood pressure in obesity via stimula-
tion of sympathetic outflow in the central nervous system
when crossing the blood-brain barrier [84].
In atherosclerosis, apelin might have beneficial effects,
as apelin has been shown to stimulate endothelial NO
production and antagonize the Ang II-induced forma-
tion of atherosclerotic lesions and aortic aneurysms in a
murine model of atherosclerosis [85].
Vasorelaxing adipokines
Adiponectin
Adiponectin is mainly released by both brown [86] and
white [69] adipocytes and is the most abundant adipo-
kine in the circulation [87]. Adiponectin has been con-
sidered an anti-inflammatory and antioxidative
adipokine that protects against cardiovascular disease
[88]. Adiponectin inhibits TNFa production and other
inflammatory pathways in adipocytes and macrophages
[40,88]. Plasma adiponectin has been correlated with
endothelium-dependent vasorelaxation in humans [89].
These results were confirmed by other studies that
have shown an increase in NO production as well as
NO-mediated and potassium channel-mediated (that
is, voltage-dependent) vasorelaxation in rats by adipo-
nectin [59,90,91]. NO release from the endothelium is
likely stimulated by adiponectin’s binding to either the
adiponectin type 2 receptor or T-cadherin on the
endothelial surface [59]. Increased NO production
inhibits platelet aggregation, leucocyte adhesion to
endothelial cells and vascular smooth muscle cell pro-
liferation. Furthermore, it reduces oxidative stress by
decreasing ROS production in endothelial cells. All of
these effects protect the vascular system against
endothelial dysfunction [88].
The use of an adiponectin receptor 1-blocking peptide
has been found to abolish the vasorelaxing effect of
human perivascular adipose tissue [59]. However, vasor-
elaxation induced by perivascular adipose tissue
remained unchanged in adiponectin gene-deficient mice
[91]. It is possible that this vasorelaxing effect of peri-
vascular adipose tissue in the adiponectin gene-deficient
mice might be the result of an endothelium-independent
pathway [92]. Despite the latter findings, adiponectin
remains an important vasoactive regulator.
Many studies on obesity-related diseases (for exam-
ple, type 2 diabetes and hypertension) [40,93], but not
all [22,94], have reported an overall decrease in adipo-
nectin levels. Hypoadiponectinemia causes endothelial
dysfunction by increasing superoxide anion production
[95] by promoting the production of adhesion mole-
cules in endothelial cells and the proliferation of
smooth muscle cells [96]. Low adiponectin levels have
recently emerged as an independent predictor of early
atherosclerosis in obese patients [96]. However, after
the establishment of atherosclerosis, this association
may become weaker, especially in the presence of con-
ditions inducing a hypercatabolic state (such as heart
or renal failure) which are associated with increased
plasma adiponectin, accelerated progression of
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atherosclerosis and worse clinical outcome [88]. In
fact, several data show that high circulating adiponec-
tin levels are associated with increased cardiovascular
mortality in patients with coronary artery disease [88].
Therefore, hypoadiponectinemia may have clinical
value at the early stages of atherogenesis, but at more
advanced disease stages its role as a meaningful bio-
marker is questionable.
Although whether low levels of adiponectin predict
hypertension remains controversial [42,97] and whether
adiponectin levels in hypertension are decreased [87,98],
low adiponectin levels might contribute to the pathogen-
esis of obesity-related hypertension. Considering all the
beneficial effects of adiponectin on the vascular system, an
antihypertensive therapy which increases adiponectin
levels could be of great value. It has already been demon-
strated in obese adiponectin-knockout mice with hyper-
tension that adiponectin replenishment lowers elevated
blood pressure [99]. Existing drugs such as peroxisome
proliferator-activated receptor g agonists (thiazolidine-
diones), some angiotensin type 1 receptor blockers (telmi-
sartan), angiotensin-converting enzyme inhibitors and
cannabinoid type 1 receptor blockers (rimonabant and tar-
anabant) have been shown to increase circulating adipo-
nectin levels [88]. However, future strategies should focus
on upregulation of adiponectin expression (and/or its
receptors) or on targeting adiponectin receptors through
the development of specific agonists.
Omentin
Omentin is a recently identified adipose tissue-derived
cytokine consisting of 313 amino acids and is mainly
expressed in visceral rather than in subcutaneous adi-
pose tissue [100]. Omentin consists of two isoforms in
which omentin-1 appears to be the major isoform in
human plasma [101]. Furthermore, higher plasma omen-
tin-1 levels were detected in women compared with
men [101]. In isolated rat aorta, omentin directly
induces an endothelium-dependent relaxation which is
mediated by NO. Omentin is even capable of inducing
vasorelaxation in an endothelium-independent way.
Omentin-induced relaxation is also observed in isolated
rat mesenteric arteries, indicating the effectiveness of
omentin in resistance vessels [100]. Since only in vitro
studies on isolated blood vessels have been performed,
in vivo studies are necessary to explore the influence of
omentin on blood pressure and its chronic influence on
vascular reactivity.
Very little is known about this novel protein in obe-
sity. What is known is that omentin plasma levels and
adipose tissue gene expression are decreased in obesity
[101] and even more when overweight is combined with
type 2 diabetes [102]. Furthermore, decreased omentin-1
levels are associated with low plasma adiponectin and
high-density lipoprotein levels. In addition, omentin-1
levels are negatively correlated with leptin levels, waist
circumference, body mass index and insulin resistance
[101]. Like adiponectin, circulating omentin-1 concen-
trations increase after weight loss-induced improvement
of insulin sensitivity [103]. Although further research is
necessary, elevating omentin levels might be of interest-
ing therapeutic value in obesity and obesity-related
disorders.
Visfatin
Visfatin is another novel identified cytokine which is
released from perivascular and visceral adipose tissue
and which has an insulin-mimetic effect [104,105]. Vis-
fatin has multiple functions in the vasculature. It stimu-
lates growth of vascular smooth muscle cells [106] and
endothelial angiogenesis via upregulating VEGF and
matrix metalloproteinases [104]. Visfatin can also
directly affect vascular contractility. Visfatin has been
shown to induce endothelium-dependent vasorelaxation
in rat isolated aorta through NO production. Also, in
mesenteric arteries of rats, visfatin induces relaxation,
suggesting that visfatin is effective in resistance vessels
[107]. Because only acute effects of visfatin have been
demonstrated, further studies are necessary to explore
the chronic influence of visfatin on vascular reactivity.
Most studies, but not all, have shown an increase in
visfatin levels in obesity [105,108]. A relationship of
plasma visfatin levels was seen with body mass index
and percentage of body fat, but not with abdominal cir-
cumference or visceral fat estimated on the basis of
computed tomography [108]. It has been reported that
the expression of visfatin is high at plaque rupture sites
in patients with coronary artery disease [109]. Visfatin
accelerates monocyte adhesion to endothelial cells by
upregulating intercellular cell adhesion molecule-1 and
vascular cell adhesion molecule (VCAM)-1 in vascular
endothelial cells due to ROS overproduction, suggesting
a possible role for visfatin in the development of athero-
sclerosis [110]. Further studies are necessary to clarify
the atherogenic and vasoactive effects of visfatin and its
potential clinical relevance.
Adipocyte-derived relaxing factor
Vascular tone can also be regulated by an unknown
ADRF which is released from perivascular adipose tis-
sue. Soltis and Cassis [111] first described that the pre-
sence of perivascular adipose tissue reduced vascular
contractions by norepinephrine in rat aorta, which was
later confirmed by Löhn et al. [6]. Also, isolated adipose
tissue and cultured rat adipocytes relaxed precontracted
rat aorta previously cleaned of adherent adipose tissue.
This modulatory effect was attributed to ADRF, which
functions as a regulator of arterial tone by active antag-
onism of contraction [6]. A similar vasorelaxing effect of
perivascular adipose tissue was observed in rat mesen-
teric arteries [112], in mouse aorta [113] and in human
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internal thoracic arteries [114]. These data suggest a
common pathway for arterial tone regulation in different
species and different types of vascular structures. Ver-
lohren et al. [112] even showed a positive correlation
between the vasorelaxing influence of ADRF and the
amount of perivascular adipose tissue. The observation
that the resting membrane potential of vascular smooth
muscle cells in arteries with adipose tissue is more
hyperpolarized than in arteries without adipose tissue,
further supports the idea that perivascular adipose tissue
actively contributes to basal arterial tone [112]. Whether
NO formation and endothelium are involved in the
vasorelaxation effect of ADRF is still a matter of debate
[6,92,112]. On the other hand, the vasorelaxing effect of
ADRF is likely mediated by the opening of different K+
channels in vascular smooth muscle cells, depending on
the tissue and species studied [6,92,112,114,115]. These
divergent observations suggest a different distribution of
K+ channels in different vessels and/or species or the
existence of different ADRFs.
More and more evidence is accumulating in support
of the existence of different ADRFs. Löhn et al. [6] first
suggested that ADRF is a protein. Furthermore, analyses
of adipose tissue secretion in a recent electrophoresis
study resulted in the visualization of different protein
bands with different molecular masses (13.8 to
74.0 kDa), which may include ADRF [116]. A possible
candidate is peptide angiotensin [1-7], which is a vaso-
dilator located within adipose tissue surrounding rat
aorta [117]. Blocking this particular peptide inhibits
the vasorelaxing effect of perivascular adipose tissue
surrounding rat aorta [117]. This hypothesis is contra-
dicted, however, by the fact that certain ADRF-related
potassium channels (KATP or Kv) [6,115] are not
involved in this observed vasorelaxing effect. In addi-
tion to proteins, hydrogen peroxide produced from the
NAD(P)H oxidase in adipocytes has been described as
being involved in the endothelium-independent path-
way of ADRF [92]. Also hydrogen sulphide has been
proposed as a novel candidate of ADRF or at least as a
mediator in the ADRF effect [115,118], which is con-
sistent with inactivation of ADRF by heating (65°C for
10 minutes) [6]. Hydrogen sulphide has recently been
described as a gasotransmitter generated by cystathio-
nine g-lyase (CSE) in perivascular adipose tissue
[119,120]. Blocking of CSE inhibits the vasorelaxing
effect of perivascular adipose tissue in rat aorta and
mouse mesenteric arteries [115,118]. Moreover, hydro-
gen sulphide-induced vasorelaxation of rat aorta was
inhibited by a particular ADRF-related potassium
channel (KCNQ) blocker [115]. However, hydrogen
sulphide generation and CSE expression in the perivas-
cular adipose tissue of stenotic aortas (but not in aor-
tic tissue) have been shown to be increased in rat
hypertension induced by abdominal aortic banding
[118], while the vasorelaxing effect of perivascular adi-
pose tissue has been shown to be impaired in sponta-
neously hypertensive rats [121]. This might indicate
that ADRFs other than hydrogen sulphide are
impaired, resulting in a reduced vasorelaxing effect of
adipose tissue. On the other hand, it is difficult to
compare both studies, as they used different models of
hypertension. Furthermore, the upregulation of CSE
and hydrogen sulphide generation in perivascular adi-
pose tissue of stenotic aortas may have developed inde-
pendently of hypertension, as CSE-knockout mice have
been shown to be hypertensive [120].
Obesity is characterized by a decrease in the vasore-
laxing effect of perivascular adipose tissue, leading to
hypertension [22,59,91,122]. This might imply a decrease
in ADRF release or an imbalance in adipose tissue-
derived relaxing and vasocontractile factors during obe-
sity. On the other hand, hypoxia, which develops within
adipose tissue during obesity [12], has recently been
shown to enhance the release of vasorelaxing factors
released from adipose tissue, which might implicate
ADRF [123]. So, the release of ADRF in obesity warrants
further research.
Vasocontractile adipokines
Angiotensinogen and Ang II
Brown and white adipocytes are rich sources of angio-
tensinogen, the precursor protein of a major vasocon-
tractile peptide called Ang II [124], and possess all the
enzymes necessary to produce Ang II [125]. These find-
ings suggest the existence of a local renin-angiotensin
system in adipose tissue. Moreover, the amount of
angiotensinogen mRNA in adipose tissue is 68% of that
in the liver, supporting an important role for adipose
angiotensinogen in Ang II production [126]. The impor-
tance of this angiotensinogen source in blood pressure
regulation by the renin-angiotensin system was shown in
wild-type and angiotensinogen-deficient mice in which
adipocyte-derived angiotensinogen was overexpressed.
When angiotensinogen expression was restricted to adi-
pose tissue (in an angiotensinogen-deficient background),
circulating angiotensinogen was detected and the mice
were normotensive. On the other hand, wild-type mice
were hypertensive because of the additional amount of
angiotensinogen that developed as a result of overexpres-
sion of adipocyte-derived angiotensinogen [127].
An important effect of Ang II is that this peptide
enhances the metabolism of NO into oxygen free radi-
cals, which damage the vascular tissue [128]. Therefore,
an imbalance between Ang II and NO leads to endothe-
lial dysfunction, resulting in a loss of vasodilator capa-
city. This results in an increased expression of adhesion
molecules and proinflammatory cytokines in endothelial
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cells, which promotes monocyte and leukocyte adhesion
and migration to the vessel wall [129]. Furthermore,
Ang II exerts detrimental effects on the progression and
destabilization of atherosclerotic plaque because of an
increased release of PAI-1, causing thrombosis and
increased expression of growth factors, which leads to
smooth muscle cell proliferation and migration [129].
Most data support an elevation of angiotensinogen
mRNA expression in adipose tissue during obesity [130].
Furthermore, several studies have highlighted a contri-
bution of adipose tissue-derived angiotensinogen and/or
angiotensin II to obesity-related hypertension [130].
High Ang II levels may deteriorate obesity-related
hypertension because of an increased secretion of proin-
flammatory cytokines [131], decreased adiponectin
secretion [132] and increased leptin production in adi-
pocytes [133].
Resistin
Resistin, which is expressed in brown and white adipose
tissue, is a member of the family of cysteine-rich proteins
called resistin-like molecules [86,134]. Resistin is secreted
into the medium by cultured adipocytes and circulates in
plasma, indicating that it is a secretory product of adi-
pose tissue. However, circulating monocytes and macro-
phages in particular seem to be responsible for resistin
production in humans [40]. Although resistin does not
directly affect the contractility of isolated blood vessels
[135], coronary blood flow, mean arterial pressure or
heart rate [136], it has been associated with endothelial
dysfunction and coronary artery disease [137].
Initial findings have been reported regarding an asso-
ciation between obesity and elevated plasma resistin
levels [138,139]. However, this finding was not confirmed
by other investigators [140,141]. Resistin expression is
stimulated by TNFa and IL-6, both of which are
increased in obesity [142], which offers an explanation
for an increased level of resistin in obesity. Resistin aug-
ments endothelin-1 release, which causes endothelial
dysfunction. Moreover, resistin impairs endothelial func-
tion with [143] or without [136] augmenting superoxide
production, resulting in decreased expression of endothe-
lial NO synthase and NO levels [144]. Resistin also aug-
ments the expression of VCAM-1 and MCP-1, both of
which are involved in early atherosclerotic lesion forma-
tion [145]. It has also been shown that high plasma resis-
tin levels are independently associated with an increased
risk for hypertension among nondiabetic women [146].
Conclusions
Adipose tissue produces and secretes several adipokines.
Some of these adipokines possess vasoactive properties
(Figure 1). Arterial tone can be controlled through the
release of ROS, leptin, adiponectin, TNFa, IL-6, Ang II,
omentin, resistin, visfatin, apelin and ADRF. The regula-
tion of arterial tone might be compromised in obesity
and obesity-related disorders (for example, type 2 dia-
betes, cardiovascular disease and hypertension) because
of alterations in the secretion of vasoactive adipokines
by dysfunctional adipose tissue. Circulating levels of adi-
ponectin and omentin are decreased, while levels of lep-
tin, resistin, apelin and proinflammatory cytokines are
increased. One therapeutic strategy to counter the pro-
gression of obesity-related vascular diseases is to elevate
adiponectin and omentin levels. Adiponectin levels are
already elevated by the use of thiazolidinediones, telmi-
sartan, angiotensin-converting enzyme inhibitors, rimo-
nabant and taranabant [88]. On the other hand, the
development of specific agonists to target adiponectin
and omentin receptors or inhibit detrimental adipokine
signalling pathways may be new and promising methods
to attenuate the proinflammatory effects and ultimately
to reduce the progression of obesity-related vascular
diseases.
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